Publications by authors named "Michael Fx Ho"
Article Synopsis
- Immune therapies like anti-CTLA4 and anti-PD1 monoclonal antibodies are improving long-term survival rates for advanced melanoma patients by achieving durable remissions in 50-60% of cases.
- Despite the high prevalence of brain metastases in advanced melanoma, most clinical trials exclude these patients, making it difficult to assess how effective immunotherapy is for them.
- Retrospective studies indicate that immunotherapy improves overall survival for melanoma patients with brain metastases compared to supportive care, and combining it with radiotherapy enhances survival outcomes, though symptomatic lesions may respond less effectively.*
